1. Undigested PCR product
2. homozygote for T235M
3. heterozygote for M235T
4. homozygore for T235M
5. heterozygote for M235T (control)
6. homozygote for T235M
7. Lader

Figure 1. Restriction fragments separated by electro­phoresis on a 2.5% agarose gel.

Description of the Population . Clinical characteristic of the hypertensive patients are given in Table 1. Males prevailed over females (65.0%). The proportion of sub­jects being administered anti-hypertensive treatment was very high (70.0%). The mean age of onset of essential hypertension was 41.5 ± 9.45. Over 80.0% of the patients had SBP between 120 and 170 mm Hg. Sixty percent of analyzed patients had one or more acquired risk factor(s).

The prevalence of angiotensinogen polymorphism M235T was significantly different between the group of hypertensive patients and controls. We found 55.0% prev­alence of angiotensinogen polymorphism M235T in the group of patients with essential hypertension compared to 32.5% prevalence in the control group. The c² test showed the a statistically significant difference (p <0.04), as shown in Table 2. The mean age of onset of essential hy­pertension in patients with detected M235T was 41.5 ± 9.45, but we found no statistical significance between the two groups. Seventy-seven percent of patients with essen­tial hypertension who carried M235T were men. Only seven patients (17.5%) had not previously received ther­apy. However, the c ² test showed no statistically signifi­cant difference. No statistically significant difference has been confirmed for M235T distribution related to ac­quired risk factor(s).